Volume Alert - SNY 46.80 Sanofi-Aventis Sa $SNY Hit a high today of 46.98 Closing the day 10:29 at 46.80 -0.34 -0.72% With a day low of 46.51 and a total volume of 990,423.
SNY Recent Posts: http://investorshangout.com/Sanofi-SNY-52680/
SNY Sanofi-Aventis Sa Recent Headline News
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 195.92 (+0.58), ABBV: 63.75 (-0.10), SNY: 46.35 (-0.79), REGN: 401.22 (+2.86)
Asthma treatment passes trial
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) jointly announced positive results from a phase 2 study of dupilumab in patients with moderate to severe uncontrolled asthma, who often struggle with daily symptoms and recurring asthma attacks. Based...
SNY: 46.35 (-0.79), REGN: 401.22 (+2.86)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.89 (-0.11), AGN: 195.92 (+0.58), ACT: 240.63 (-3.00), VRX: 131.03 (+1.00), MDT: 68.56 (-0.43), SLXP: 95.97 (-3.04), SNY: 46.35 (-0.79)
PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:20AM CST
PDL BioPharma (PDLI) reported third-quarter 2014 earnings of 61 cents per share, well above the year-ago earnings of 36 cents per share.
AMAG: 34.99 (+0.11), SNY: 46.35 (-0.79), PDLI: 8.07 (-0.04)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.18 (-0.19), AZN: 74.19 (-0.01), AMGN: 162.07 (-0.35), TEVA: 58.45 (+0.26), THRX: 13.26 (+0.33), GSK: 45.49 (-0.47), SNY: 46.35 (-0.79), REGN: 401.22 (+2.86), NVS: 92.63 (-0.14)
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
PR Newswire - Tue Nov 11, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
SAN: 8.22 (-0.18), SNY: 46.35 (-0.79), REGN: 401.22 (+2.86)
Look for Shares of Sanofi-Aventis to Potentially Pullback after Yesterday's 1.09% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:29PM CST
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $45.96 to a high of $46.42. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $46.02 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 46.35 (-0.79)
Sanofi-Aventis Set to Possibly Pullback After Yesterday's Rally of 1.09%
Comtex SmarTrend(R) - Mon Nov 10, 4:29PM CST
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $45.96 to a high of $46.42. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $46.02 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 46.35 (-0.79)
3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.27 (unch), SNY: 46.35 (-0.79), GNW: 8.77 (+0.37), REGN: 401.22 (+2.86)
MannKind Is On The Mend
Nicholas Kitonyi - at Seeking Alpha - Fri Nov 07, 6:07PM CST
NVO: 44.17 (-0.16), PFE: 30.42 (+0.10), LLY: 67.57 (-0.28), MNKD: 6.07 (+0.03), SNY: 46.35 (-0.79)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 320.94 (-3.65), ALNY: 100.40 (+1.93), ISIS: 51.76 (+0.37), OGXI: 2.10 (-0.05), TEVA: 58.45 (+0.26), RGLS: 19.87 (-0.60), GSK: 45.49 (-0.47), SNY: 46.35 (-0.79)
Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST
ALNY: 100.40 (+1.93), MDCO: 25.15 (+0.73), SNY: 46.35 (-0.79)
VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:45PM CST
VIVUS Inc.'s (VVUS) third-quarter 2014 loss of 11 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 21 cents.
AUXL: 32.56 (-0.04), VVUS: 3.27 (unch), AMAG: 34.99 (+0.11), SNY: 46.35 (-0.79)
All Eyes on ISIS Pharmaceuticals, Inc.'s Pipeline
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 2:17PM CST
Isis Pharmaceuticals releases earnings on Friday, but don't expect the company to give investors much information about the launch of its approved drug, Kynamaro. The drug is sold by Isis' marketing partner Sanofi , which doesn't break out sales...
ISIS: 51.76 (+0.37), SNY: 46.35 (-0.79)
Today's Market: Earnings And News Moving These 5 Stocks
Matthew Smith - at Seeking Alpha - Thu Nov 06, 9:01AM CST
TSLA: 249.40 (-1.68), PRGO: 154.68 (-0.76), QCOM: 70.17 (+0.53), AZN: 74.19 (-0.01), SNY: 46.35 (-0.79)
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis
DoctoRx - at Seeking Alpha - Thu Nov 06, 7:32AM CST
AMGN: 162.08 (-0.34), SNY: 46.35 (-0.79), REGN: 401.22 (+2.86)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 100.40 (+1.93), AMGN: 162.08 (-0.34), SNY: 46.35 (-0.79), REGN: 401.22 (+2.86)
Momenta Pharmaceuticals, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 1:32PM CST
At this point, earnings calls for Momenta Pharmaceuticals are more an opportunity to update investors than to report revenue and earnings. Because, let's face it... sales of Momenta's and Novartis ' enoxaparin, a generic version of Sanofi 's ...
BAX: 71.25 (+0.49), TEVA: 58.45 (+0.26), ABBV: 63.76 (-0.09), SNY: 46.35 (-0.79), MNTA: 10.45 (-0.47), NVS: 92.63 (-0.14)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 106.92 (-0.37), ENDP: 67.85 (-0.41), AUXL: 32.56 (-0.04), SHPG: 200.67 (-1.54), DNDN: 0.17 (+0.02), SNSS: 1.65 (-0.03), ABBV: 63.76 (-0.09), SNY: 46.35 (-0.79), MNKD: 6.07 (+0.03), XOMA: 4.11 (+0.07)
SNY Recent Posts: http://investorshangout.com/Sanofi-SNY-52680/
SNY Sanofi-Aventis Sa Recent Headline News
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 195.92 (+0.58), ABBV: 63.75 (-0.10), SNY: 46.35 (-0.79), REGN: 401.22 (+2.86)
Asthma treatment passes trial
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) jointly announced positive results from a phase 2 study of dupilumab in patients with moderate to severe uncontrolled asthma, who often struggle with daily symptoms and recurring asthma attacks. Based...
SNY: 46.35 (-0.79), REGN: 401.22 (+2.86)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.89 (-0.11), AGN: 195.92 (+0.58), ACT: 240.63 (-3.00), VRX: 131.03 (+1.00), MDT: 68.56 (-0.43), SLXP: 95.97 (-3.04), SNY: 46.35 (-0.79)
PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:20AM CST
PDL BioPharma (PDLI) reported third-quarter 2014 earnings of 61 cents per share, well above the year-ago earnings of 36 cents per share.
AMAG: 34.99 (+0.11), SNY: 46.35 (-0.79), PDLI: 8.07 (-0.04)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.18 (-0.19), AZN: 74.19 (-0.01), AMGN: 162.07 (-0.35), TEVA: 58.45 (+0.26), THRX: 13.26 (+0.33), GSK: 45.49 (-0.47), SNY: 46.35 (-0.79), REGN: 401.22 (+2.86), NVS: 92.63 (-0.14)
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
PR Newswire - Tue Nov 11, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
SAN: 8.22 (-0.18), SNY: 46.35 (-0.79), REGN: 401.22 (+2.86)
Look for Shares of Sanofi-Aventis to Potentially Pullback after Yesterday's 1.09% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:29PM CST
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $45.96 to a high of $46.42. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $46.02 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 46.35 (-0.79)
Sanofi-Aventis Set to Possibly Pullback After Yesterday's Rally of 1.09%
Comtex SmarTrend(R) - Mon Nov 10, 4:29PM CST
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $45.96 to a high of $46.42. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $46.02 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 46.35 (-0.79)
3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.27 (unch), SNY: 46.35 (-0.79), GNW: 8.77 (+0.37), REGN: 401.22 (+2.86)
MannKind Is On The Mend
Nicholas Kitonyi - at Seeking Alpha - Fri Nov 07, 6:07PM CST
NVO: 44.17 (-0.16), PFE: 30.42 (+0.10), LLY: 67.57 (-0.28), MNKD: 6.07 (+0.03), SNY: 46.35 (-0.79)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 320.94 (-3.65), ALNY: 100.40 (+1.93), ISIS: 51.76 (+0.37), OGXI: 2.10 (-0.05), TEVA: 58.45 (+0.26), RGLS: 19.87 (-0.60), GSK: 45.49 (-0.47), SNY: 46.35 (-0.79)
Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST
ALNY: 100.40 (+1.93), MDCO: 25.15 (+0.73), SNY: 46.35 (-0.79)
VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:45PM CST
VIVUS Inc.'s (VVUS) third-quarter 2014 loss of 11 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 21 cents.
AUXL: 32.56 (-0.04), VVUS: 3.27 (unch), AMAG: 34.99 (+0.11), SNY: 46.35 (-0.79)
All Eyes on ISIS Pharmaceuticals, Inc.'s Pipeline
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 2:17PM CST
Isis Pharmaceuticals releases earnings on Friday, but don't expect the company to give investors much information about the launch of its approved drug, Kynamaro. The drug is sold by Isis' marketing partner Sanofi , which doesn't break out sales...
ISIS: 51.76 (+0.37), SNY: 46.35 (-0.79)
Today's Market: Earnings And News Moving These 5 Stocks
Matthew Smith - at Seeking Alpha - Thu Nov 06, 9:01AM CST
TSLA: 249.40 (-1.68), PRGO: 154.68 (-0.76), QCOM: 70.17 (+0.53), AZN: 74.19 (-0.01), SNY: 46.35 (-0.79)
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis
DoctoRx - at Seeking Alpha - Thu Nov 06, 7:32AM CST
AMGN: 162.08 (-0.34), SNY: 46.35 (-0.79), REGN: 401.22 (+2.86)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 100.40 (+1.93), AMGN: 162.08 (-0.34), SNY: 46.35 (-0.79), REGN: 401.22 (+2.86)
Momenta Pharmaceuticals, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 1:32PM CST
At this point, earnings calls for Momenta Pharmaceuticals are more an opportunity to update investors than to report revenue and earnings. Because, let's face it... sales of Momenta's and Novartis ' enoxaparin, a generic version of Sanofi 's ...
BAX: 71.25 (+0.49), TEVA: 58.45 (+0.26), ABBV: 63.76 (-0.09), SNY: 46.35 (-0.79), MNTA: 10.45 (-0.47), NVS: 92.63 (-0.14)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 106.92 (-0.37), ENDP: 67.85 (-0.41), AUXL: 32.56 (-0.04), SHPG: 200.67 (-1.54), DNDN: 0.17 (+0.02), SNSS: 1.65 (-0.03), ABBV: 63.76 (-0.09), SNY: 46.35 (-0.79), MNKD: 6.07 (+0.03), XOMA: 4.11 (+0.07)
